Abstract
Melanoma is the most dangerous type of skin cancer, and pre 2011 the prognosis of metastatic melanoma was very poor. In developing countries, such as Brazil, a vast majority of patients do not have access to the opportunity of an early, curative melanoma approach and this leads to metastatic disease. In this sense, the purpose of this paper is to illustrate the distinct lack of access to innovative melanoma treatments, based on immunotherapy and target therapy, in the public and private health sectors in Brazil. We analyzed the Brazilian health regulatory system and the incorporation of health technologies in the public and private health settings. At present, for patients being treated within the public health system, only dacarbazine is available. Whereas, immune-oncology agents and target therapies are available for patients being treated within the private health sector. In this scenario, we concluded that the introduction of innovations could accentuate the existing inequalities in the delivery of healthcare in Brazil.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
